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Biomarkers of aging associated with past treatments in breast
cancer survivors
Zorica Scuric1, Judith E. Carroll2,3,4, Julienne E. Bower2,3,4,5, Sam Ramos-Perlberg1, Laura Petersen4, Stephanie Esquivel2,3, Matt Hogan1,
Aaron M. Chapman1, Michael R. Irwin2,3, Elizabeth C. Breen2,3, Patricia A. Ganz 1,4 and Robert Schiestl1,2,6
Radiation and chemotherapy are effective treatments for cancer, but are also toxic to healthy cells. Little is known about whether
prior exposure to these treatments is related to markers of cellular aging years later in breast cancer survivors. We examined
whether past exposure to chemotherapy and/or radiation treatment was associated with DNA damage, telomerase activity, and
telomere length 3–6 years after completion of primary treatments in breast cancer survivors (stage 0–IIIA breast cancer at
diagnosis). We also examined the relationship of these cellular aging markers with plasma levels of Interleukin (IL)-6, soluble TNF-
receptor-II (sTNF-RII), and C-reactive protein (CRP). Ninety-four women (36.4–69.5 years; 80% white) were evaluated. Analyses
adjusting for age, race, BMI, and years from last treatment found that women who had prior exposure to chemotherapy and/or
radiation compared to women who had previously received surgery alone were more likely to have higher levels of DNA damage
(P = .02) and lower telomerase activity (P = .02), but did not have differences in telomere length. More DNA damage and lower
telomerase were each associated with higher levels of sTNF-RII (P’s < .05). We found that exposure to chemotherapy and/or
radiation 3–6 years prior was associated with markers of cellular aging, including higher DNA damage and lower telomerase
activity, in post-treatment breast cancer survivors. Furthermore, these measures were associated with elevated inflammatory
activation, as indexed by sTNF-RII. Given that these differences were observed many years after the treatment, the findings suggest
a long lasting effect of chemotherapy and/or radiation exposure.
npj Breast Cancer  (2017) 3:50 ; doi:10.1038/s41523-017-0050-6
INTRODUCTION
Successful treatment of cancer has dramatically increased the
number of cancer survivors, largely through the application of
multi-modal therapies, including surgery, radiation, chemother-
apy, and biotherapy.1–3 However, the potential for long-term
detrimental impact of these treatments and their consequences to
health and quality of life for survivors is of increasing concern.4,5
Indeed, cancer survivors are at increased risk for earlier disability,
chronic disease, and death, raising the possibility that some cancer
treatments may accelerate the aging process.2,5–12 Among child-
hood cancer survivors in particular, the accumulated burden of
chronic conditions has been attributed to the exposure to these
lifesaving treatments and their late effects, often leading to
premature death in comparison to unaffected sibling controls.7
Less is known about the potential for treatment-associated
increased morbidity and acceleration in aging among adult
cancer survivors, although as more long-term studies are done
in adult survivors, similar concerns have been advanced.5,12–14
Radiation and many chemotherapeutic agents are cytotoxic,
resulting in damage to cancer cells and the ultimate death of
these cells when treatment is successful. Non-cancer cells are also
affected by these same treatments, resulting in death of cells in
normal tissues. When a significant amount of damage
accumulates within a cell from either radiation or cytotoxic
chemotherapy, the cell will either initiate apoptosis leading to cell
death, or growth arrest to enable the cell to repair the damage.
When the damage exceeds internal capacity to repair, the growth
arrest becomes permanent, a state referred to as cellular
senescence. Senescent cells are considered a key player in the
aging process.15,16 Senescent cells are sources of inflammation,
releasing numerous secretory factors, including cytokines, che-
mokines, and various damage-associated molecular patterns that
propagate and promote inflammatory activity from other cells and
in nearby tissue microenvironments.17–19 This milieu of inflamma-
tory secretory factors further promotes aging processes and has
been implicated in increased vulnerability to cancer, cardiovas-
cular disease, diabetes, dementia, frailty, arthritis, and numerous
other diseases of aging.20 Thus, diseases and conditions seen in
advancing age develop as a consequence of cellular aging
pathways, including senescence.
Recent animal models have characterized the impact of
chemotherapy on the accumulation of senescent cells,21 and
clinical studies have documented elevated levels of DNA
damage22 and increased expression of p16INK4a, a marker of
senescence, within T cells of patients after chemotherapy.23 In
parallel, studies have shown an increase in inflammatory markers
during radiation and/or chemotherapy24–26 that may persist long
Received: 27 June 2017 Revised: 25 October 2017 Accepted: 31 October 2017
1UCLA Fielding School of Public Health, Los Angeles, CA, USA; 2Department of Psychiatry & Biobehavioral Sciences, UCLA David Geffen School of Medicine, Los Angeles, CA, USA;
3Cousins Center for Psychoneuroimmunology, UCLA Semel Institute for Neuroscience and Human Behavior, Mail Code 707624, 300 Medical Plaza, Suite 3330, Los Angeles, CA
90095-7076, USA; 4UCLA Jonsson Comprehensive Cancer Center, 650 Charles Young Drive South, Room A2-125 CHS, Los Angeles, CA 90095-6900, USA; 5UCLA Department of
Psychology, Los Angeles, CA, USA and 6UCLA Departments of Pathology, Environmental Health, and Radiation Oncology, and UCLA School of Public Health, Los Angeles, CA, USA
Correspondence: Judith E. Carroll (jcarroll@mednet.ucla.edu)
Zorica Scuric and Judith E. Carroll contributed equally to this work.
www.nature.com/npjbcancer
Published in partnership with the Breast Cancer Research Foundation
after treatment completion.12,27 Additional markers of the
biological aging process that may be relevant in the context of
cancer treatments include telomere length, a repeat sequence of
DNA at the end or chromosomes, which shortens with cellular
replication and can initiate senescence, and telomerase activity, an
enzyme that rebuilds telomeres,28 but whose function is no longer
necessary in senescent cells. While some evidence suggests
cancer treatments do not impact leukocyte telomere length,23,29
others have reported shorter telomere length among cancer
survivors.30–32 Thus, whether cancer treatment impacts telomere
length is inconclusive. On the other hand, whether cancer
treatment impacts peripheral blood telomerase activity has not
been tested. In the current study we examine the hypothesis that
both chemotherapy and radiation will be associated with markers
of biological aging, including higher levels of white blood cell
(WBC) DNA damage, lower peripheral blood mononuclear cell
(PBMC) telomerase activity, and shorter PBMC telomere length,
that are all hallmarks of aged cells.15 We test this hypothesis in a
well-characterized cohort of breast cancer survivors from the mind
body study (MBS).25,33 In addition, given the link between cellular
aging processes and inflammation, we also predicted that these
cellular aging biomarkers would be related to proinflammatory
secretory factors in breast cancer patients years after treatment
completion.
RESULTS
Participant characteristics
Ninety-four women were assessed at the MBS final visit (TF), 3–6
years after the initial diagnosis of breast cancer. Blood samples of
satisfactory quantity and quality for analyses were available for
total WBC DNA damage (N = 94), PBMC telomerase activity (N = 84;
telomerase product generated (TPG) per 10,000 cells M[SD] = 22.7
[19.4]), PBMC telomere length (N = 87; M[SD] = .72[.27]), and
plasma cytokines (N = 94; IL-6 pg/mL M[SD] = 1.3[.99]; sTNF-RII,
pg/mL M[SD] = 2228.4; C-reactive protein (CRP), mg/L M[SD] = 2.4
[2.7]). Descriptive information on the complete MBS cohort has
been reported elsewhere,25,33 and those who participated in the
TF visit are representative of the full sample. Table 1 presents the
descriptive data for these women overall, and stratified according
to surgery or chemotherapy and/or radiation exposure (our
primary case-control analysis). Additional supplementary tables
report descriptive information for patients by various treatment
subtypes (e.g., radiation alone, chemotherapy alone, and both
radiation and chemotherapy combined; Supplement Table 1). In
chemotherapy and/or radiation-exposed group compared to
surgery alone, the demographic characteristics were similar;
however, the surgery alone group had lower stage disease, were
more likely to have mastectomies, and had lower rates of
endocrine therapy, as would be expected.
Initial analyses examined whether demographic factors were
related to our biological outcomes of interest. Age and longer
time since treatment were associated with higher DNA damage
(P < .002; P = .002). Other demographics were unrelated to DNA
damage. We also tested for a possible role of current comorbid-
ities as they might relate to our biological markers, including
presence of allergies, arthritis, asthma, diabetes, glaucoma, heart
disease, and hypertension, and found no statistical differences in
frequency of these conditions by DNA damage group, and no
significant mean differences in PBMC telomere length or WBC
telomerase activity, with the exception of significantly lower
telomerase activity in those with allergies (P = .02). With respect to
PBMC telomerase activity, declines were observed with increasing
age (r = −.23, P = .04), and shorter PBMC telomere length was
associated with high BMI (r = −.21, P < .05). No other demographic
factors related to these biomarkers. Subsequent models adjusted
for age, race, BMI, and years since last treatment.
Chemotherapy and/or radiation exposure
To test our primary hypothesis that the overall effect of prior
chemotherapy and radiation exposures would relate to markers of
biological aging, we examined the effects of chemotherapy and/or
radiation exposure on markers of cellular aging at TF (see Table 2).
In adjusted models controlling for age, race, BMI, and years since
last treatment, women who had been exposed to chemotherapy
and/or radiation (i.e., any therapy in addition to surgery) were
significantly more likely to have high levels of DNA damage
compared to women who received surgery alone (P = .02; see
Fig. 1). In addition, women exposed to chemotherapy and/or
radiation had significantly lower telomerase activity compared to
surgery alone (P = .02), and further adjustment for comorbid
allergies did not modify this effect. Figure 2 presents the mean
and standard error (SE) for telomerase enzymatic activity
separated by exposure. Additional adjustment for endocrine
therapy did not alter these effects (P’s remain <.05). The effect
of chemotherapy and/or radiation exposure was associated with
slightly higher mean values of sTNF-RII (2272 vs. 2038 pg/mL,
P = .15), although not statistically significant. There were no
Table 1. Participant medical and demographic characteristics
Total
sample
Surgery
alone
Chemo and/
or radiation
P-value
N= 94 N= 15 N= 79
Age, mean (SD) 56.5 (8.1) 58.1 (5.4) 56.2 (8.5) .39
Body mass index
(BMI), mean (SD)
25.7 (5.1) 26.0 (5.6) 25.6 (5.0) .79
Years since diagnosis,
mean (SD)
4.8 (0.7) 4.7 (.60) 4.8 (.68) .50
Years since last
treatment, mean (SD)
4.4 (0.6) 4.6 (.57) 4.4 (.65) .16
Race, % White 80% 86.7% 78.5% .47
Marital status, %
Married
62.8% 53.3% 64.6% .41
Education .82
Post college 50% 53.3% 49.4%
College 31% 33.3% 30.4%
No college degree 19% 13.3% 20.3%
Employment status .08
Full or part-time 73% 86.7% 63.3%
Not employed 27% 13.3% 36.7%
Annual household
income
.54
≥$100,000 59.6% 66.7% 58.2%
<$100,000 40.4% 33.3% 41.8%
Post-menopausal 80.9% 53% 51% .93
Past hormone
therapy (HT)
33.3% 28.6% 34.2% .68
Surgery .000
Mastectomy 34% 80% 25.3%
Lumpectomy 66% 20% 74.7%
Stage at diagnosis .000
Stage 0 16% 53.3% 8.9%
Stage I 46% 46.7% 45.6%
Stage II 31% 0% 36.7%
Stage III 7% 0% 8.9%
Endocrine therapy 72% 40% 78.5% .002
Had chemotherapy 54.2% 0% 64.6%
Had radiation 72% 0% 86.1%
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differences in PBMC telomere length by exposure group.
The Supplementary File and Supplemental Table 3 further explore
the effect of radiation, chemotherapy, the combined effect of
receiving both, and the type of chemotherapeutic agent on these
aging markers.
Inflammation and biomarkers of aging
To determine the relationship of circulating markers of inflamma-
tion with biological aging indices we ran additional regression
analyses. In adjusted models, sTNF-RII was related to DNA damage,
such that women with high DNA damage exhibited significantly
higher levels of sTNF-RII, B(SE) = 349.8(127.5), P = .007 (see Fig. 3),
and modestly higher, but not significant, IL-6, B(SE) = .44(.24),
P = .08. No associations were observed between DNA damage and
CRP (P = .73). Telomerase activity was also associated with sTNF-RII
levels, with lower telomerase activity related to marginally higher
levels of sTNF-RII, B(SE) = −36.34(19.2), P = .06. Telomerase was
unrelated to IL-6 (P = .90) and CRP (P = .57). Telomere length was
unrelated to any of the inflammatory markers (P’s > .35).
DISCUSSION
Among the breast cancer survivors in the present analyses, we
report significantly greater DNA damage and lower levels of
telomerase enzymatic activity among women who had been
exposed to chemotherapy and/or radiation therapy, compared to
those who had not received either of these treatments. These
differences were detectable even though exposure had occurred
3–6 years prior to the current study visit. Specifically, having been
exposed to chemotherapy and/or radiation was associated with
the highest levels of DNA damage and lower telomerase activity,
both markers of greater cellular aging. Increased DNA damage has
Table 2. Multivariate analyses examining treatment exposure type predicting biomarkers of aging parameters at final visit (TF) adjusting for age,
race, BMI, and years from treatment
WBC DNA damage (high damage vs. low) PBMC telomerase (deciles) PBMC telomere length (T/S)
Predictor β(SE)a OR(95% CI)b P-value β(SE) Betac P-value β(SE) Beta P-value
Covariates in the model
Age (years) 0.15(.05) 1.16(1.06, 1.28) .002 −0.09(.04) −0.23 .04 −0.004(.004) −0.11 .32
Race (White= 1) 1.14(1.23) 3.14(0.35, 28.59) .31 0.05(.91) 0.007 .96 −0.11(.08) −0.17 .16
Body mass index (kg/m2) 0.007(.06) 1.01(0.89, 1.14) .92 −0.04(.07) −0.07 .54 −0.01(.006) −0.23 .04
Years from treatment 1.49(.47) 4.44(1.77, 11.16) .002 −0.17(.48) −0.04 .73 −0.05(.05) −0.11 .32
Treatment exposure
Chemotherapy and/or radiationd 2.92(1.26) 18.49(1.56, 218.9) .02 −1.93(.83) −0.25 .02 0.07(.08) 0.09 .39
a Standard coefficient (β) and standard error (SE)
b Odds ratio (OR) and 95% confidence interval (95% CI)
c Unstandardized regression coefficient (Beta)
d Compared to those receiving neither treatment, a surgery alone group (N= 15)
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Fig. 1 Percentage of breast cancer survivors with high DNA damage
(top quartile) with either past exposure to chemotherapy and/or
radiation or surgery alone. OR(95% CI)= 18.49(1.56, 218.9), P= .02
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Fig. 2 Estimated marginal mean ± SE of PBMC telomerase enzy-
matic activity (TPG per 10,000 cells) in breast cancer survivors with
either past treatment exposure to chemotherapy and/or radiation or
surgery alone, adjusting for age, race, BMI, and years from treatment
exposure. B(SE)= −1.93(.83), P= .02. Note: Figure displays mean
scores from non-transformed data, while statistical analyses use
transformed telomerase activity (deciles) due to non-normal
distribution in TPG values
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been reported in breast cancer survivors compared to healthy
controls, although treatment-specific effects were not reported.22
In our analyses, greater DNA damage and lower telomerase
activity were also associated with elevations in inflammatory
activity, as indicated by sTNF-RII levels. sTNF-RII is a downstream
marker of activity of the pro-inflammatory cytokine TNF-alpha,
which is shed upon upregulation of inflammation via the TNF
pathway.34,35 Elevated levels of sTNF-RII indicate activation of
inflammation, with further implication for aging given the role of
TNF-alpha in the proinflammatory secretory profile of senescent
cells.17–19 Our previous work has demonstrated that sTNF-RII was
the only elevated inflammatory marker during the first 6 months
after finishing chemotherapy.33 The current findings suggest that
exposure to cancer treatments that include chemotherapy and/or
radiation are associated with longer-term increases in DNA
damage and reductions in telomerase activity, indicators of
biological aging that coincide with higher levels of inflammatory
activation, including sTNF-RII in the present sample.
We did not observe differences in telomere length related to
treatment exposure. However, we did see a significant relationship
of PBMC TL with BMI, consistent with an independent association
of adiposity with greater replicative cellular aging as indexed by
shortened TL.36 These results are similar to other reports
suggesting exposure to chemotherapy and radiation treatments
may not consistently be related to blood cell telomere length
shortening per se, but rather may drive aging via induction of DNA
damage and cell senescence.23,29–32 Indeed, telomere length
shortening occurs by cell replication, a process often halted during
cancer treatments. Cellular senescence, on the other hand, is
reached through either replicative exhaustion or cell stress
pathways (i.e., DNA damage). Cellular aging among breast cancer
patients may therefore occur independent of the telomere ends,
and be driven more so by DNA damage.15,16 Our results contribute
to a growing literature that proposes certain cancer treatment
exposures may leave a lasting imprint on cellular biology by
linking it to DNA damage, a pathway to cellular senescence.
Previous studies have linked effects of breast cancer treatment
(chemotherapy and/or radiation) to higher levels of inflammatory
markers,12,24–26,33 and separately, to elevated levels of a marker of
cellular senescence, p16INK4a.23 The current study adds to this
research by directly capturing cell level DNA damage and
telomerase enzymatic activity, and examining treatment-specific
exposures and associations with pro-inflammatory cytokine levels
measured from the same blood draw. Further research may
benefit from the inclusion of a broader panel of markers of
systemic inflammatory activity that are known to be released from
senescent cells and a better characterization of DNA damage in
treatment-exposed cancer survivors using markers like hOGG1 to
discriminate between oxidative and non-oxidative damage.37 Host
factors may also play an important role in determining the extent
and duration of the damage seen in treatment-exposed cancer
patients and associated inflammation, and further examination of
patient-specific variability, such as genetic variants (e.g., hOGG1
variant S326C-OGG138) that influence DNA repair capacity is
warranted. Similarly, telomere length has also been found to be
partially determined by genetic factors and inheritance,39,40 and
future work should consider the role this might play.
Limitations exist in the current analyses. The cross-sectional
nature of the study limits causal attribution. For example, although
inflammatory cytokines are released from aged cells, this is not the
only source, and the directionality of these relationships remains
uncertain. Inflammation is also a recognized cause of aging,41 and
further work should disentangle this in the context of cancer
treatment exposure effects.20 Along this line, it is also possible that
the treatments themselves are not directly responsible for
increased DNA damage. Rather the biology of the cancer may
dictate treatment regimen that contributes to lasting differences
in DNA damage, although animal models do not support this
conclusion. It is also possible that unmeasured differences exist
between those receiving surgery alone compared to chemother-
apy or radiation treatments that explains the differences in
biomarkers of aging we report. Although, as can be seen in
Table 1, the surgery only group appears to be similar to the other
treatment group on the majority of demographic and medical
factors, with the exception of being earlier stage, type of surgery
received, and whether treated with endocrine therapy. Further
adjustment by endocrine therapy in our models did not alter our
results. Further research that assesses DNA damage using a within
patient design, examining DNA damage prior to treatment
exposure and years later, may help answer this remaining
possibility. Likewise, future animal research could more carefully
test this hypothesis by employing well-designed experimental
models of cancer treatment exposures (e.g., radiation/chemother-
apy), and observe pre-to-post DNA damage, telomerase activity,
cellular senescence, and inflammatory activity from multiple cell
sources. Moreover, our measure of DNA damage was in whole
blood, while telomerase was assessed in purified mononuclear
cells. DNA damage from treatment is most likely to be retained
years later in the PBMC pool, rather than in all leukocytes.
Neutrophils (predominant cell in whole blood leukocytes are not
present in PBMCs) are short lived in circulation (e.g., weeks), while
many of the other cells found in PBMCs remain in circulation for
years. Future studies may want to consider whether examining
DNA damage in PBMCs, rather than all leukocytes, may yield even
more meaningful and relevant information regarding the lasting
impact of treatment exposures on DNA damage. Further research
is warranted in cancer survivors that provide a stronger link
between these elevated markers of aging with subsequent risk for,
or exacerbation of, existing comorbid conditions associated with
aging. The current study has several strengths that should be
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(three lower quartiles) DNA damage groups adjusting for age, race,
BMI, and years from treatment exposure. B(SE)= 349.8(127.5),
P= .007
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noted. First, the study examines a well-characterized cohort of
breast cancer survivors with medically verified reports of cancer
treatment exposure who were then followed for several years after
treatment. Second, the measurement of cellular DNA damage and
telomerase activity, and linking this to inflammation in breast
cancer survivors is novel and represents a unique and promising
direction for future research.
CONCLUSION
In conclusion, we followed breast cancer patients for 3–6 years
after completion of primary treatment and found that those who
had been exposed to chemotherapy and/or radiation exhibited
elevated levels of DNA damage in peripheral blood cells and lower
telomerase enzymatic activity. Both high DNA damage and low
telomerase activity were associated with elevated levels of sTNF-
RII, a biomarker of proinflammatory activation. These results are
consistent with existing evidence that exposure to certain cancer
treatments have a lasting impact on biological aging pathways, in
particular the accumulation of senescent cells, and further suggest
that elevated damage to DNA may be mechanisms through which
senescent cells are formed in cancer patients. These findings
support the hypothesis that cancer survivors may be vulnerable to
accelerated aging due to the lasting effects of chemotherapy and
radiation exposure.
METHODS
Participants
Participants in the current study were from the UCLA MBS, a longitudinal,
prospective cohort study of 190 women with early stage breast cancer
enrolled after the end of primary breast cancer treatment, and prior to
initiating adjuvant endocrine therapy, if indicated.25,33,42–44 All procedures
were approved by the University of California, Los Angeles, Institutional
Review Board, and all participants provided informed consent. The MBS
study was designed primarily to examine changes in cognitive function
with endocrine therapy, and thus women older than 65 years were
excluded so as not to confound age-related cognitive changes. Initial MBS
eligibility criteria included women with diagnosis of stage 0–IIIA breast
cancer who had completed their primary cancer treatment within the past
3 months, but had not yet started endocrine therapy. Women could have
no major immune-related conditions such as an autoimmune disease, and
no evidence of uncontrolled depressive symptoms or neurological
conditions. Serial evaluation across numerous domains of biological
parameters, cognitive functioning, quality of life, and behavioral symptoms
were conducted, and details of patient recruitment from tumor registry
listings and direct referral from nearby hospitals and medical oncology
practices located near the University of California, Los Angeles, are
described in our previous publications.25,33,42–44 The initial study included
three in-person visits, 6 months apart, during the year after primary
treatment ended. MBS participants who completed the 12-month
assessment were approached to be in the Long-Term Follow-Up Study,
which consisted of annual mailed survey questionnaires and a final in-
person visit (TF) that replicated the in-person assessments that had been
performed during the first year. Initial study enrollment extended over
more than 3 years, resulting in a TF visit that varied from 3–6 years from
initial breast cancer treatment. Although 134 completed the TF
questionnaire, only 94 attended the in-person visit to provide a fasting
morning blood specimen. No differences in medical or demographic data
were found among those who provided a blood specimen compared to
those who did not at the time of the TF visit. The women seen at the TF
visit had remained disease free, with no recurrence of breast cancer.
Investigators completing the biological assays were blind to treatment
exposure of participants.
WBC DNA damage
Whole blood samples collected in EDTA tubes were combined with a
freezing medium (RPMI + 20% DMSO) and stored at −80 °C until further
analyses. DNA damage was determined using the comet assay as reported
in Singh et al.45 with minor modifications. The comet assay is a single cell
gel electrophoresis assay that assessed the extent of DNA damage in
nucleated WBC. Cells were thawed and suspended in PBS buffer (Sigma-
Aldrich, St. Louis, MO.) which was then added to a 1% low melting agarose
(pre-warmed at 37 °C) (LMA, Cat. No. 15517-022, Invitrogen, Life
Technologies, Carlsbad, CA). This cell suspension was then placed in rings
made in a normal melt agarose gel (BP-160-500, Fisher Scientific, Fair Lawn,
NJ) previously poured on hydrophilic side of Gel Bond Film (GelBond® Film,
Cat. No. 53734, Cambrex Bio Science Inc., Rockland, ME). Samples were run
in triplicate and included positive (normal cells treated with 0.1 M H2O2)
and negative controls (normal cells without treatment). Gel with samples
loaded was then treated with a lysis buffer (100mM Na2EDTA pH 10, 2.5 M
NaCl, 1% Triton X-100, 10 mM Tris, 10% DMSO) at 4 °C for 1 h. Gel was then
washed 3× with neutralizing buffer (0.4 M Tris, pH 7.5), and then placed in
the electrophoresis chamber with alkaline buffer (0.3 M NaOH, 1mM
Na2EDTA, pH > 13) for 20min at 4 °C. Electrophoresis was performed in the
dark for 45min, 25 V, and 300mA at 4 °C, the gel was washed with a
neutralizing buffer (0.4 M Tris, pH 7.5). Samples were stained with SYBR
Gold (Molecular Probes, Eugene, OR) for visualization of the DNA. Olympus
BX51 fluorescent microscope and DP72 camera attached to a FITC filter
(Olympus, Cypress, CA) was used to capture images of 100 or more comets
containing nuclei. Images were then imported into CASP software (CASP,
Wroclaw, Poland) for determination of tail size (length, intensity, area) and
head size (radius, intensity, area), and calculations of percentage of DNA in
the head and tail. The extent of DNA damage is reported using data from
approximately 100 comets per sample using Olive Tail Moment (OTM)
values, derived from the percentage of DNA in the tail × distance between
the center of the tail and the center of the head. Distribution of DNA
damage was not normal, with analyses showing high kurtosis (8.8),
resulting in uneven representation of low scores. We created a top quartile
cutoff to characterize higher DNA damage (range = 0.8–4.7 OTM) and
compare this to the remaining sample with an average low DNA damage
scores (range = 0.01–0.79 OTM).
PBMC telomerase activity
To determine telomerase activity, the telomere repeat amplification
protocol (TRAP) was performed as previously described with minor
modification.46,47 Standard density centrifugation of heparinized whole
blood was used to isolate PBMC. Cells were suspended in CHAPS lysis
buffer at a concentration of 5000 PBMC per microliter, lysed on ice for 30
min, and then spun at 14,500 rpm at 4° for 20min. Supernatant was frozen
at −80 °C until further analysis. For the assay, thawed telomerase extract
equivalent to 15,000 PBMC was mixed with dH2O, 10× TRAP reaction
buffer, dNTPs, Cy5-labeled TS primer (5′-ATTCGGTCGACGAGACTT-3′), ACX
primer (5′-GCGCGGCTTACCCTTACCCTTACCCTAACC-3′), TSNT (5′-
AATCCGTCGAGCAGAGTTAAAAGGCCGAGAAGCGAT-3′), NT primer (5′-
ATCGCTTCTCGGCCTTTT-3′), and Platinum Taq for a total volume of 45 µL
per reaction. PCR was run as follows, step1: 30 °C for 30min (1×), step 2: 94 °C
for 2 min (1×), then step 3: 94 °C for 30 s, 60 °C for 30 s, 72 °C for 60 s
(repeat 28×), and step 4: 72 °C for 60 s. Samples are then frozen at −20 °C
before being run in a 12.5% acrylamide gel, which is set up as follows: two
negative controls (heat inactivated cell extract per sample and a CHAPS
only well containing no cell extract), two positive controls (a telomerase
product quantification standard, TSR8, and cell extract with known high
telomerase activity), and product generated from sample extracts. As
extracts from whole blood may contain PCR inhibitors,47 TSNT serves as an
internal control. Gels were scanned using a GE Healthcare Typhoon 9410
Variable Mode Imager. Calculation of TPG per 10,000 cells is performed
using ImageQuant and calculated as follows: (product generated from the
sample)−(heat-treated lane)/(TSNT internal control × 100). This is then
divided by (TSR8−CHAPS)/TSNT of TSR8. Values are calculated as total TPG
per 10,000 cells, and then transformed to deciles to reduce skew and
kurtosis in the distribution of values.
PBMC telomere length
Detailed methods for the assessment of PBMC telomere length have been
reported previously.48,49 Briefly, telomere length was determined using
standard quantitative polymerase chain reaction methods originally
developed by Cawthon.50 DNA is extracted from PBMC isolated from
heparinized whole blood, using DNeasy Blood and Tissue kits (Qiagen).
Samples are run in triplicate on two plates, one for the telomere (TEL) DNA
repeats (T) and one for HGB single copy gene (S). Standard curves are
generated on each plate to confirm optimal PCR efficiency is obtained,
90–105% and to control for plate-to-plate variations. Inter-assay and intra-
assay CV’s were below 10%. Values for PBMC telomere length are
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expressed as a ratio of TEL to HGB as T/S, which reflects the estimated
concentration of the telomere DNA repeat divided by the single copy
gene.
Circulating inflammatory markers: soluble TNF receptor II (sTNF-
RII), interleukin(IL)-6, and CRP
Consistent with previous MBS reports,25,33 blood samples were collected
at the TF study visit by venipuncture into EDTA tubes, chilled, and
centrifuged for the collection of plasma. Aliquots of plasma were then
stored at −80 °C until batch testing could be performed on all TF samples.
Soluble tumor necrosis factor (TNF) receptor type II (sTNF-RII) and
Interleukin(IL)-6 were assessed using regular and high-sensitivity
enzyme-linked immunosorbent assays (ELISAs; R&D Systems, Minneapolis,
MN) per manufacturer’s protocol; lower limits of detection were 234 and
0.2 pg/mL, respectively. CRP levels were determined by a high-sensitivity
ELISA (Immundiagnostik, ALPCO Immunoassays, Salem, NH) according to
the manufacturer’s protocol, but with an extended standard curve to a
lower limit of detection of 0.2 mg/L. All samples were run in duplicate with
an average intra-assay precision of less than 5%; inter-assay precision for
sTNF-RII, IL-6, and CRP was 4, 12, and 6%, respectively.
Statistical analyses
Statistical analyses were performed using IBM SPSS for Windows version
23. Variables were assessed for normal distribution and transformed as
described above. Linear and logistic regression analyses were run, entering
age, BMI, race, and time since treatment as covariates on the first step, and
next entering on step 2 treatment type compared to surgery alone on DNA
damage, telomerase activity, and telomere length (T/S). First, to determine
the overall impact of exposure to either type of treatment, we examined
the effect of treatment with chemotherapy and/or with radiation therapy
exposure compared to surgery alone. In secondary analyses, we then
examined whether chemotherapy and radiation therapy exposure may
have distinct effects on cellular aging, we tested whether each of these
treatment exposures were uniquely related to outcomes individually
compared to surgery alone (see Supplemental Files) using separate
regression analyses for each treatment type. Further regression analyses
were run to test the relationship of DNA damage, telomerase activity, and
telomere length with circulating markers of inflammation (sTNF-RII, IL-6,
and CRP). In Table 2 we report adjusted odds ratio (OR) with confidence
interval (CI) and unstandardized regression coefficients (β) with SE to
provide effect size estimates given multiple comparisons.
Data availability
The data that support the findings of this study are available from the
corresponding author upon reasonable request.
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